Tariquidar

Tariquidar

Clinical data
ATC code	none
Identifiers
IUPAC name N-[2-[[4-[2-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]-4,5-dimethoxyphenyl]quinoline-3-carboxamide
CAS Number	206873-63-4 Y
PubChem CID	148201
ChemSpider	130650 N
UNII	J58862DTVD
ChEMBL	ChEMBL348475 N
E number	{{#property:P628}}
CompTox Dashboard (EPA)	{{#property:P3117}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C38H38N4O6
Molar mass	646.744 g·mol−1
3D model (JSmol)	Interactive image
SMILES COC1=C(C=C2CN(CCC2=C1)CCC3=CC=C(C=C3)NC(=O)C4=CC(=C(C=C4NC(=O)C5=CC6=CC=CC=C6N=C5)OC)OC)OC
InChI InChI=1S/C38H38N4O6/c1-45-33-18-25-14-16-42(23-28(25)19-34(33)46-2)15-13-24-9-11-29(12-10-24)40-38(44)30-20-35(47-3)36(48-4)21-32(30)41-37(43)27-17-26-7-5-6-8-31(26)39-22-27/h5-12,17-22H,13-16,23H2,1-4H3,(H,40,44)(H,41,43) N Key:LGGHDPFKSSRQNS-UHFFFAOYSA-N N
NY (what is this?)  (verify)

Tariquidar (INN/USAN) is a potent P-glycoprotein inhibitor and a substrate of breast cancer protein (BCRP/ABCG2) undergoing research as an adjuvant against multi-drug resistance in cancer.

Tariquidar progressed to phase III clinical trials in combination with vinorelbine in an effort to enhance the efficacy of this chemotherapeutic agent. However, several of these trials were terminated early due to adverse effects, and further development of Tariquidar was subsequently halted.